Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01658995 · ClinicalTrials.gov registry record · Phase 3
Management of Etonogestrel Subdermal Implant-related Bleeding
A Phase 3 study of ESI-related Bleeding, sponsored by Petra M. Casey.
- Completed
- Registry status
- Phase 3
- Development phase
- 82
- Enrollment target
- 1
- Study location
NCT01658995 is a Phase 3 study of ESI-related Bleeding that has completed, run by Petra M. Casey. The registered enrollment target is 82 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01658995, a Phase 3 study of ESI-related Bleeding, has completed, sponsored by Petra M. Casey.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 82 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a double-blinded, randomized, prospective placebo-controlled clinical trial to be conducted within the Mayo Clinic and the Mayo Clinic Health System. The goal of the research study is to gather information to determine whether Doxycycline is effective for the treatment of unacceptable bleeding associated with the etonogestrel subdermal implant (ESI), as compared to placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Doxycycline
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2012-09-13 |
| Est. Completion | 2019-12-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01658995
The ClinicalTrials.gov registry entry for NCT01658995 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Petra M. Casey, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with ESI-related Bleeding appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01658995 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT01658995 about?
NCT01658995 is a clinical study titled "Management of Etonogestrel Subdermal Implant-related Bleeding". This is a double-blinded, randomized, prospective placebo-controlled clinical trial to be conducted within the Mayo Clinic and the Mayo Clinic Health System. The goal of the research study is to gather information to determine whether Doxycycline is effective for the treatment of unacceptable bleed...
What is the current status of trial NCT01658995?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 82 participants. The study started on 2012-09-13. Estimated completion is 2019-12-30.
What conditions does trial NCT01658995 study?
This clinical trial studies the following conditions: ESI-related Bleeding.
What interventions are being tested in trial NCT01658995?
The interventions under investigation include: Placebo (DRUG), Doxycycline (DRUG).
Who is sponsoring clinical trial NCT01658995?
This trial is sponsored by Petra M. Casey, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01658995 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.